Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763259 | 0.80 | PTGDR2 (0.41) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL1199476 | 0.78 | ELANE (0.61) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL870959 | 0.76 | ALDH1A1 (0.55) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| Benzene SCHEMBL3155472 | 0.74 | ALDH1A1 (0.58) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL1978896 | 0.74 | ALDH1A1 (0.59) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL28063651 | 0.72 | ALDH1A1 (0.61) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL9120033 | 0.72 | ALDH1A1 (0.61) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| Naphthalene SCHEMBL3150577 | 0.72 | KMT2A (0.52) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL17103353 | 0.72 | ALDH1A1 (0.66) | PTGDR2ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL29246389 | 0.71 | GAA (0.51) | HTTSMN1; SMN2LMNAGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493905-B1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT CO LLC (PR) | 2016-11-30 | — | — | EP | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8710215-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2493905-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | Warner Chilcott Company, LLC (PR) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056589-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | PTGDR2 249/4885ALDH1A1 2404/4885HPGD 358/4885 |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | PTGDR2 249/4885ALDH1A1 2404/4885HPGD 358/4885 |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | PTGDR2 249/4885ALDH1A1 2404/4885HPGD 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.